Funds › Velan Capital Investment Management LP
Velan Capital Investment Management LP
13F for Q2 2026, filed Aug 14, 2026. 50 positions worth $164.2M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Velan Capital Investment Management LP in the latest 13F quarter?
Using 13F.ai, how has Velan Capital Investment Management LP's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Velan Capital Investment Management LP's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q2 2026
Largest first. Common shares only; puts and calls are under All positions.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | PRAX Praxis Precision Medicines, Inc. | 88,781 | $29.7M | 18.1% | -11.9% | 13F ↗ |
| 2 | MPLT MapLight Therapeutics, Inc. | 492,893 | $17.7M | 10.8% | Unchanged | 13F ↗ |
| 3 | STRO Sutro Biopharma, Inc. | 512,160 | $17.0M | 10.4% | Unchanged | 13F ↗ |
| 4 | IMMX Immix Biopharma, Inc. | 1.08M | $11.2M | 6.8% | +46.6% | 13F ↗ |
| 5 | TARA Protara Therapeutics, Inc. | 2.84M | $10.9M | 6.6% | +0.4% | 13F ↗ |
| 6 | ABVX Abivax SA · ADR | 65,630 | $8.7M | 5.3% | -14.8% | 13F ↗ |
| 7 | TENX Tenax Therapeutics, Inc. | 549,985 | $8.0M | 4.9% | -5.7% | 13F ↗ |
| 8 | AVR Anteris Technologies Global Corp. | 700,000 | $6.9M | 4.2% | Unchanged | 13F ↗ |
| 9 | EDSA Edesa Biotech, Inc. | 827,500 | $6.7M | 4.1% | Unchanged | 13F ↗ |
| 10 | EVMN Evommune, Inc. | 451,255 | $6.0M | 3.7% | +1.1% | 13F ↗ |
| 11 | AVTX Avalo Therapeutics, Inc. | 324,452 | $6.0M | 3.7% | +75.3% | 13F ↗ |
| 12 | XNCR Xencor, Inc. | 255,000 | $4.1M | 2.5% | +2.0% | 13F ↗ |
| 13 | RZLT Rezolute, Inc. | 750,000 | $3.9M | 2.4% | Unchanged | 13F ↗ |
| 14 | HRTX Heron Therapeutics, Inc. | 8.75M | $3.7M | 2.3% | Unchanged | 13F ↗ |
| 15 | VRCA Verrica Pharmaceuticals Inc. | 471,559 | $2.9M | 1.8% | Unchanged | 13F ↗ |
| 16 | CCCC C4 Therapeutics, Inc. | 570,000 | $2.7M | 1.6% | New | 13F ↗ |
| 17 | EPRX Eupraxia Pharmaceuticals Inc. · Com 298736 Al 3 Euronet Worldwide Inc Note 0.750% 3/1 | 352,000 | $2.3M | 1.4% | Unchanged | 13F ↗ |
| 18 | ADMA ADMA Biologics Inc | 250,000 | $2.1M | 1.3% | New | 13F ↗ |
| 19 | RNTX Rein Therapeutics, Inc. | 1.70M | $1.8M | 1.1% | New | 13F ↗ |
| 20 | LYEL Lyell Immunopharma, Inc. | 105,000 | $1.5M | 0.9% | +2.9% | 13F ↗ |
| 21 | NSRX Nasus Pharma Ltd. | 359,390 | $1.3M | 0.8% | Unchanged | 13F ↗ |
| 22 | PROF Profound Medical Corp. | 170,278 | $1.1M | 0.7% | -40.4% | 13F ↗ |
| 23 | JSPR Jasper Therapeutics, Inc. | 2.67M | $1.1M | 0.7% | Unchanged | 13F ↗ |
| 24 | PTGX Protagonist Therapeutics, Inc. | 3,700 | $453.5K | 0.3% | Unchanged | 13F ↗ |
| 25 | CTMX CytomX Therapeutics, Inc. | 120,000 | $450.0K | 0.3% | -77.8% | 13F ↗ |
| 26 | NMRA Neumora Therapeutics, Inc. | 230,000 | $391.0K | 0.2% | +188% | 13F ↗ |
| 27 | NRIX Nurix Therapeutics, Inc. | 16,000 | $388.2K | 0.2% | Unchanged | 13F ↗ |
| 28 | OVID Ovid Therapeutics Inc. | 130,000 | $349.7K | 0.2% | -18.8% | 13F ↗ |
| 29 | DTIL Precision BioSciences, Inc. | 40,000 | $314.4K | 0.2% | Unchanged | 13F ↗ |
| 30 | MLYS Mineralys Therapeutics, Inc. | 11,000 | $296.8K | 0.2% | Unchanged | 13F ↗ |
| 31 | MGNX MacroGenics, Inc. | 60,000 | $277.2K | 0.2% | +100% | 13F ↗ |
| 32 | CRBP Corbus Pharmaceuticals Holdings, Inc. | 26,000 | $243.9K | 0.1% | Unchanged | 13F ↗ |
| 33 | ARTV Artiva Biotherapeutics, Inc. | 25,000 | $242.5K | 0.1% | Unchanged | 13F ↗ |
| 34 | REPL Replimune Group, Inc. | 20,000 | $221.4K | 0.1% | Unchanged | 13F ↗ |
| 35 | SNDX Syndax Pharmaceuticals, Inc. | 10,000 | $218.6K | 0.1% | Unchanged | 13F ↗ |
| 36 | IMNM Immunome, Inc. | 10,000 | $211.9K | 0.1% | Unchanged | 13F ↗ |
| 37 | TECX Tectonic Therapeutic, Inc. | 6,000 | $206.3K | 0.1% | New | 13F ↗ |
| 38 | RCKT Rocket Pharmaceuticals, Inc. | 60,000 | $205.2K | 0.1% | -79.6% | 13F ↗ |
| 39 | KPTI Karyopharm Therapeutics Inc. | 20,000 | $195.4K | 0.1% | +33.3% | 13F ↗ |
| 40 | ANTX AN2 Therapeutics, Inc. | 40,000 | $193.6K | 0.1% | New | 13F ↗ |
| 41 | VRDN Viridian Therapeutics, Inc. | 10,000 | $183.7K | 0.1% | -89.0% | 13F ↗ |
| 42 | SCYX SCYNEXIS, Inc. | 40,000 | $162.8K | 0.1% | New | 13F ↗ |
| 43 | QNRX Quoin Pharmaceuticals, Ltd. · ADR | 32,372 | $156.7K | 0.1% | -61.8% | 13F ↗ |
| 44 | XLO Xilio Therapeutics, Inc. | 14,285 | $136.8K | 0.1% | Unchanged | 13F ↗ |
| 45 | NSPR InspireMD Inc. | 148,138 | $103.7K | 0.1% | -92.9% | 13F ↗ |
| 46 | KLRS Kalaris Therapeutics, Inc. | 25,000 | $101.8K | 0.1% | +38.9% | 13F ↗ |
| 47 | LRMR Larimar Therapeutics, Inc. | 33,000 | $100.7K | 0.1% | Unchanged | 13F ↗ |
| 48 | PRQR ProQR Therapeutics N.V. · Shs Euro | 45,000 | $83.7K | 0.1% | Unchanged | 13F ↗ |
| 49 | CNTX Context Therapeutics Inc. | 59,700 | $33.1K | <0.1% | -40.3% | 13F ↗ |
| 50 | Gossamer Bio Inc | 70,000 | $11.5K | <0.1% | Unchanged | 13F ↗ |
Changes since Q1 2026
6 new, 10 added to, 11 trimmed, 5 exited, 23 unchanged. By estimated dollars.
New positions (6)
Added to (10)
| IMMX Immix Biopharma, Inc. | 1.08M | +46.6% | $3.6M |
| AVTX Avalo Therapeutics, Inc. | 324,452 | +75.3% | $2.6M |
| NMRA Neumora Therapeutics, Inc. | 230,000 | +188% | $255.0K |
| MGNX MacroGenics, Inc. | 60,000 | +100% | $138.6K |
| XNCR Xencor, Inc. | 255,000 | +2.0% | $80.5K |
| EVMN Evommune, Inc. | 451,255 | +1.1% | $66.5K |
| KPTI Karyopharm Therapeutics Inc. | 20,000 | +33.3% | $48.9K |
| LYEL Lyell Immunopharma, Inc. | 105,000 | +2.9% | $42.1K |
| TARA Protara Therapeutics, Inc. | 2.84M | +0.4% | $38.2K |
| KLRS Kalaris Therapeutics, Inc. | 25,000 | +38.9% | $28.5K |
Trimmed (11)
| PRAX Praxis Precision Medicines, Inc. | 88,781 | -11.9% | -$4.0M |
| CTMX CytomX Therapeutics, Inc. | 120,000 | -77.8% | -$1.6M |
| ABVX Abivax SA · ADR | 65,630 | -14.8% | -$1.5M |
| VRDN Viridian Therapeutics, Inc. | 10,000 | -89.0% | -$1.5M |
| NSPR InspireMD Inc. | 148,138 | -92.9% | -$1.4M |
| RCKT Rocket Pharmaceuticals, Inc. | 60,000 | -79.6% | -$802.5K |
| PROF Profound Medical Corp. | 170,278 | -40.4% | -$767.6K |
| TENX Tenax Therapeutics, Inc. | 549,985 | -5.7% | -$485.2K |
| QNRX Quoin Pharmaceuticals, Ltd. · ADR | 32,372 | -61.8% | -$254.0K |
| OVID Ovid Therapeutics Inc. | 130,000 | -18.8% | -$80.7K |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
All positions
Search, sort and filter every position, with puts and calls on their own tab. Premium plan.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q2 2026.
Filings
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer